Mitsui Chemicals Launches New Corporate Venture Capital Fund ‘321Catalyst™’
Mitsui Chemicals, Inc. (Tokyo: 4183; President & CEO: HASHIMOTO Osamu), a global chemicals manufacturer based in Japan, today announced the launch of its second Corporate Venture Capital Fund ‘321Catalyst™,’ as well as the establishment of a new subsidiary ‘321Catalyst Ventures, Inc.,’ which will manage the fund.
Building on the success of its first fund, ‘321FORCE™,’ launched with Japanese venture capital Global Brain in 2022, 321Catalyst™’s mission will be to accelerate the building of global innovation partnerships and the launching of new products and business. Through the establishment of the new, independent fund in the USA, Mitsui Chemicals is doubling down on global investments in innovative startups that align with its strategic focus. Strong innovation partnerships with its portfolio companies will allow Mitsui Chemicals to launch new businesses ahead of the race. 321Catalyst™ will have a fund size of $60 million and a life of 10 years.
Mitsui Chemicals intends to enhance and strengthen its Basic Strategy of ‘building solutions-based business models’ as manifested in its Long-Term Business Plan, VISION 2030. Consistent with this goal, Mitsui Chemicals will continue investing in startups across the world to escalate the launching of new products and new businesses as well as the transformation of its business portfolio.
Overview of 321Catalyst™, the new Corporate Venture Capital Fund | |
Registered Name | 321Catalyst LP |
Address | San Jose, CA, USA |
Fund Size | $60 million |
Date of Establishment | May 6th, 2025 |
Fund Life | 10 years |
Focus Stage | Seed and at all stages beyond |
Focus Region | Global (USA, Europe, Asia, etc.) |
Focus Industry | All industries including Life & Healthcare, Mobility, ICT, Sustainability, and other new industries |
General Partner | 321Catalyst Ventures, Inc. |
Limited Partner | 321Indigo Ventures, Inc. (100% subsidiary of Mitsui Chemicals) |
Overview of the new subsidiary acting as the General Partner | |
Registered Name | 321Catalyst Ventures, Inc. |
Address | San Jose, CA, USA |
Representative | Shunsuke Fujii (President) |
Business Overview | Management of Corporate Venture Capital Funds |
Date of Establishment | April 10th, 2025 |
Ownership | 100% owned by Mitsui Chemicals America, Inc |
View source version on businesswire.com: https://www.businesswire.com/news/home/20250526416724/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FES Super Extends Partnership with SS&C28.5.2025 00:13:00 CEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced the Fire and Emergency Services Superannuation Fund (“FES Super”) has signed a long-term agreement to extend its existing partnership with SS&C. The renewal reinforces SS&C’s leadership and continued growth in the Australian superannuation market, following several recent strategic wins in the region. FES Super leverages SS&C Bluedoor, a cloud-hosted registry platform, to manage its administration needs. The platform enables real-time automation and straight-through processing, helping streamline operations and improving member experiences. SS&C also provides member digital and reporting services to the fund. “Our top priority is acting in the best interests of our members,” said Adrian Rutter, Fund Secretary at FES Super. “SS&C’s flexible, customizable tools and consistent service enable us to continue doing just that. By leveraging Bluedoor’s integration capabilities and cloud-native services, we can efficiently deliver
Perma-Pipe International Holdings, Inc. Announces New Contract Award in Qatar27.5.2025 21:48:00 CEST | Press release
Perma-Pipe International Holdings, Inc. (Nasdaq: PPIH) today announced that it has received its first project award to be executed in Qatar since the announcement of the intent to mobilize there. The project will be for USD $2.4 million and will utilize Perma-Pipe’s fabrication capabilities and the XTRU-THERM® insulation system, a spray-applied polyurethane foam jacketed with a high-density polyethylene casing. Adham Sharkawy, Senior Vice President of Perma-Pipe’s MENA region, remarked, “In response to this important award, we will begin executing the project from a temporary facility in Doha, ensuring timely delivery and uninterrupted service to our client. Simultaneously, we are advancing the construction of our permanent facility in Qatar, which will serve as a long-term base for our regional operations. We are deeply grateful to our customers for their continued trust and confidence in Perma-Pipe’s capabilities.” Saleh Sagr, President, commented, “Expanding in Doha has been an impo
Galderma Intends to Buy Back approximately 2.4 Million Shares in the Context of the Accelerated Bookbuild Offering by EQT, ADIA and Auba27.5.2025 17:46:00 CEST | Press release
Galderma Group AG (SWX:GALD): Ad hoc announcement pursuant to Art. 53 LR Galderma intends to repurchase approximately 2.4 million shares in the context of the accelerated bookbuild offering of Galderma shares by Sunshine SwissCo GmbH (“EQT”), Abu Dhabi Investment Authority (“ADIA”) and Auba Investment Pte. Ltd. (“Auba”) announced today The repurchased shares will be held in treasury and financed by existing liquidity at hand Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it intends to repurchase approximately 2.4 million Galderma shares in the context of an accelerated bookbuilding offering (“ABO”) of approximately 16.7 million Galderma shares (approximately 7% of Galderma’s share capital) by EQT, ADIA and Auba. Galderma will participate in the ABO at the same price per share which will be determined in the bookbuilding. The repurchased shares will be financed by Galderma’s existing liquidity on hand and will not affect the company’s ability to de
New South Wales Minister for Industry and Trade Visits Novotech Seoul Office to Strengthen Clinical Trial Collaboration27.5.2025 17:44:00 CEST | Press release
Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase, was honored to welcome The Hon. Anoulack Chanthivong, New South Wales (NSW) Minister for Industry and Trade, to its Seoul office on May 19. The Minister’s visit highlights a deepening collaboration between South Korea and Australia in the field of clinical research and highlights the strategic importance of cross-border partnerships in advancing global drug development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250527294947/en/ Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase, was honored to welcome The Hon. Anoulack Chanthivong,
LambdaTest Introduces Automation MCP Server to Revolutionize Test Failure Triaging27.5.2025 17:00:00 CEST | Press release
~New server connects AI assistants directly to test execution data, streamlining debugging and accelerating development~ LambdaTest, a unified agentic AI and cloud engineering platform, has announced the launch of its Automation MCP Server, a breakthrough solution designed to simplify and accelerate the process of triaging test failures. By enabling direct integration between AI assistants and LambdaTest’s test execution data, the Automation MCP Server empowers developers and QA engineers to investigate and resolve issues faster, without leaving their integrated development environment (IDE). The Automation MCP Server offers a seamless interface within the IDE, allowing users to access and analyze real-time test data with ease. With intelligent root cause analysis, the MCP server can quickly identify the underlying reasons for test failures and take immediate action to fix the underlying code. This results in fewer debugging cycles and faster release times. The server also enhances aut
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom